Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial

Tenax Therapeutics (Nasdaq:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that Stanford University School of Medicine has been activated as the first clinical research site for the Company’s Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).

As quoted in the press release:

Anthony DiTonno, CEO of Tenax Therapeutics, Inc., stated, “We are very excited to have activated our first site for the HELP trial. We are equally excited that so many highly regarded medical centers and principal investigators have indicated strong interest in participating in the trial and we expect to have several additional site activations in the coming weeks.”

The HELP trial is designed to evaluate the hemodynamic benefits of levosimendan, compared to placebo in patients with PH-HFpEF. In addition to the previously conducted preclinical and clinical studies, the trial design has been informed by the substantial clinical experience that comes from more than one million patients who have been treated in over 60 countries where levosimendan is currently approved to treat acute heart failure.

PH-HFpEF represents an area of very high unmet medical need. No approved or effective therapies currently exist to treat the many patients who suffer with PH-HFpEF. Preliminary data from preclinical and clinical studies of pulmonary hypertension and heart failure patients provide a reason to believe that levosimendan may provide important benefits for PH-HFpEF patients.

Click here to read the full press release.